Reduction-alkylation strategies for the modification of specific monoclonal antibody bisulfides

Bioconjugate Chemistry

Volumn 16, Issue 5, 2005, Pages 1282-1290

  Sun, Michael M C ^a   Beam, Kevin S ^a   Cerveny, Charles G ^a   Hamblett, Kevin J ^a   Blackmore, Richard S ^a   Torgov, Michael Y ^a   Handley, Felicia G M ^a   Ihle, Nathan C ^a   Senter, Peter D ^a   Alley, Stephen C ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATION; AMINO ACIDS; CHAINS; CONTROLLED DRUG DELIVERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; MONOCLONAL ANTIBODIES; REDUCING AGENTS;

% REDUCTIONS; BIOLOGICAL PROPERTIES; DIAGNOSTIC APPLICATIONS; HOMOGENEOUS MATERIALS; LIGHT CHAIN; PRECISE CONTROL; SITE-SPECIFIC; SMALL MOLECULES; SPECIFIC CONJUGATIONS; STRUCTURAL APPLICATIONS;

SULFUR COMPOUNDS;

ANTIMITOTIC AGENT; CD30 ANTIGEN; CYSTEINE DERIVATIVE; DISULFIDE; DITHIOTHREITOL; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CAC10; MONOMETHYLAURISTATIN E; REDUCING AGENT; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY ELECTROPHORESIS; CHROMATOGRAPHY; CONJUGATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG EFFICACY; DRUG PURIFICATION; IN VITRO STUDY; IN VIVO STUDY; ISOMER; MOUSE; NONHUMAN; OXIDATION; REACTION ANALYSIS; REDUCTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 25444507922     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc050201y     Document Type: Article

References (33)

1. Senter, P. D., and Springer, C. J. (2001) Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Delivery Rev. 53, 247-64.
2. Sharkey, R. M., and Goldenberg, D. M. (2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46 Suppl 1, 115S-27S.
3. Trail, P. A., King, H. D., and Dubowchik, G. M. (2003) Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol. Immunother. 52, 328-37.
4. Bohdiewicz, P. J. (1998) Indium-111 satumomab pendetide: the first PDA-approved monoclonal antibody for tumor imaging. J. Nucl. Med. Technol. 26,155-63; quiz 170-1.
5. Van de Wiele, C., Revets, H., and Mertens, N. (2004) Radioimmunoimaging. Advances and prospects. Q. J. Nucl. Med. Mol. Imaging 48, 317-25.
6. Porstmann, T., and Kiessig, S. T. (1992) Enzyme immunoassay techniques. An overview. J Immunol. Methods 150, 5-21.
7. Lichlyter, D. J., Grant, S. A., and Soykan, O. (2003) Development of a novel FRET immunosensor technique. Biosens. Bioelectron. 19, 219-26.
8. Wisdom, G. B. (2005) Conjugation of antibodies to fluorescein or rhodamine. Methods Mol. Biol. 295, 131-4.
9. Gudmundsson, B. M., Young, N. M., and Oomen, R. P. (1993) Characterisation of residues in antibody binding sites by chemical modification of surface-adsorbed protein combined with enzyme immunoassay. J. Immunol. Methods 158, 215-27.
10. Wines, B. D., and Easterbrook-Smith, S. B. (1990) Carbo-diimide cross-linking of human C1q and rabbit IgG. Mol. Immunol. 27, 221-6.
11. Casey, J. L., Coley, A. M., Tilley, L. M., and Foley, M. (2000) Green fluorescent antibodies: novel in vitro tools. Protein Eng. 13, 445-52.
12. Hayashi, N., Kipriyanov, S., Fuchs, P., Welschof, M., Dorsam, H., and Little, M. (1995) A single expression system for the display, purification and conjugation of single-chain antibodies. Gene 160, 129-30.
13. Schneider, P. (2000) Production of recombinant TRAIL and TRAIL receptor. Fc chimeric proteins. Methods Enzymol. 322, 325-45.
14. Siemers, N. O., Kerr, D. E., Yarnold, S., Stebbins, M. R., Vrudhula, V. M., Hellstrom, I., Hellstrom, K. E., and Senter, P. D. (1997) Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Bioconjugate Chem. 8, 510-9.
15. Rodwell, J. D., Alvarez, V. L., Lee, C., Lopes, A. D., Goers, J. W., King, H. D., Powsner, H. J., and McKearn, T. J. (1986) Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc. Natl. Acad. Sci. U.S.A. 83, 2632-6.
16. Chang, I. N., Lin, J. N., Andrade, J. D., and Herron, J. N. (1995) Photoaffinity labeling of antibodies for applications in homogeneous fluoroimmunoassays. Anal. Chem. 67, 959-66.
17. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-84.
18. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellstrom, I., and Hellstrom, K. E. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261, 212-5.
19. Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., Law, C. L., Doronina, S. O., Siegall, C. B., Senter, P. D., and Wahl, A. F. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458-65.
20. Saphire, E. O., Stanfield, R. L., Crispin, M. D., Parren, P. W., Rudd, P. M., Dwek, R. A., Burton, D. R., and Wilson, I. A. (2002) Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319, 9-18.
21. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kassler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-70.
22. Wahl, A. F., Klussman, K., Thompson, J. D., Chen, J. H., Francisco, L. V., Risdon, G., Chace, D. F., Siegall, C. B., and Francisco, J. A. (2002) The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 62, 3736-42.
23. Mandy, W. J., and Nisonoff, A. (1963) Effect of Reduction of Several Disulfide Bonds on the Properties and Recombination of Univalent Fragments of Rabbit Antibody. J. Biol. Chem. 238, 206-213.
24. Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M., Doronina, S. O., Siadak, A. W., Senter, P. D., and Wahl, A. F. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-52.
25. Olson, J. S. (1981) Numerical analysis of kinetic ligand binding data. Methods Enzymol. 76, 652-67.
26. Sears, D. W., and Beychok, S. (1977) Acquisition of the covalent quaternary structure of an immunoglobulin G molecule. Theoretical reoxidation models. Biochemistry 16, 2026-31.
27. Sears, D. W., Mohrer, J., and Beychok, S. (1977) Relative susceptibilities of the interchain disulfides of an immunoglobulin G molecule to reduction by dithiothreitol. Biochemistry 16, 2031-5.
28. Virella, G., and Parkhouse, R. M. (1973) Sensitivity to reduction of human immunoglobulin G of different heavy chain subclasses. Immunochemistry 10, 213-7.
29. Hermanson, G. (1996) Bioconjugate Techniques, Academic Press, San Diego.
30. Kato, K., Hamaguchi, Y., Fukui, H., and Ishikawa, E. (1976) Enzyme-linked immunoassay. Conjugation of rabbit anti-(human immunoglobulin G) antibody with beta-D-galactosidase from Escherichia coli and its use for human immunoglobulin G assay. Eur. J. Biochem. 62, 285-92.
31. Palmer, J. L., Nisonoff, A., and Vanholde, K. E. (1963) Dissociation of Rabbit Gamma Globulin into Subunits by Reduction and Acidification. Proc. Natl. Acad. Sci. U.S.A. 50, 314-21.
32. Harris, L. J., Larson, S. B., Hasel, K. W., and McPherson, A. (1997) Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36, 1581-97.
33. Saphire, E. O., Parren, P. W., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R., and Wilson, I. A. (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155-9.